Clinical Trials · NCT06373731
ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)
- Phase
- Phase 3
- Recruitment status
- Active Not Recruiting
- Sponsor
- Stealth BioTherapeutics Inc.
- Enrollment
- 313
- Start date
- May 2024
- Locations
- 53 sites, 8 countries
- Primary endpoint
- Week 48 Rate of change in the macular area of photoreceptor loss